X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration will use NeoPhore's proprietary small molecule inhibitors of DNA mismatch repair to investigate single agent activity against tumours with defined genetic backgrounds.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: NeoPhore
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 18, 2023
Details:
The collaboration combines the strengths and resources of both organisations to bring forward the development of novel therapies for cancer patients worldwide.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Apollo Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 14, 2022
Details:
The treatment combination comprised VS-6766 and defactinib, which can potentially hinder signals ovarian cancer to grow. VS-6766 is a dual RAF/MEK inhibitor of Verastem Oncology while defactinib is a FAK inhibitor.
Lead Product(s): VS-6766,Defactinib
Therapeutic Area: Oncology Product Name: VS-6766
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2021
Details:
The OlympiA trial showed that adding olaparib for one year following standard treatment for patients who had an inherited BRCA mutation and early-stage, HER-2 negative breast cancer, cut the risk of their breast cancer returning by 42 per cent at a median 2.5-year follow-up.
Lead Product(s): Olaparib
Therapeutic Area: Oncology Product Name: Lynparza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2021
Details:
Study suggests that therapies which target CD38-such as the multiple myeloma drug daratumumab-could hold promise against prostate cancer too, by reawakening the anti-cancer immune response.
Lead Product(s): Daratumumab
Therapeutic Area: Oncology Product Name: Darzalex
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 07, 2021
Details:
Ellipses Pharma has rapidly progressed the development of EP0042 following successful negotiations between the ICR and the company, which were led by our Business and Innovation Office.
Lead Product(s): EP0042
Therapeutic Area: Oncology Product Name: EP0042
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ellipses Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2021
Details:
The BRAF drug, called PLX4720, which targets this genetic mutation, was developed at the ICR, and produces significant results in both thyroid cancers and melanomas which carry the mutation.
Lead Product(s): PLX4720,Talimogene laherparepvec,Antibodies
Therapeutic Area: Oncology Product Name: PLX4720
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oracle Cancer Trust
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2020
Details:
VAC2 demonstrated remarkably potent induction of immune responses in all patients dosed to date, with high levels of peripheral antigen-specific immunogenicity observed at multiple time points and confirmed by multimer staining.
Lead Product(s): VAC2
Therapeutic Area: Oncology Product Name: AST-VAC2
Highest Development Status: Phase IProduct Type: Vaccine
Recipient: Lineage Cell Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
